기관지폐이형성증(BPD) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Bronchopulmonary Dysplasia (BPD) Emerging Therapy and TPP Insights

Thelansis's "Bronchopulmonary Dysplasia (BPD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic respiratory morbidity of prematurity, predominantly afflicting extremely low birth weight (ELBW) infants born prior to 28 weeks of gestation. In the modern post-surfactant era, the pathogenesis of "new BPD" is fundamentally characterized by a critical arrest of both alveolarization and pulmonary microvascular development-resulting in fewer, larger, and highly simplified alveoli-driven by the synergistic, iatrogenic insults of mechanical ventilation (volutrauma and barotrauma) and oxygen toxicity acting upon a profoundly immature and highly inflammatory respiratory system. Clinically defined by a sustained requirement for supplemental oxygen or positive pressure respiratory support at 36 weeks post-menstrual age, the disease initiates a catastrophic cascade that heavily predisposes surviving infants to lifelong sequelae, most notably severe pulmonary hypertension, reactive airway disease, and significant neurodevelopmental impairment. Because definitive pharmacological cures remain elusive, the modern therapeutic paradigm relies heavily on aggressive prevention and lung-protective strategies. The standard of care strictly prioritizes the avoidance of invasive intubation by leveraging early non-invasive continuous positive airway pressure (CPAP), synergistically combined with targeted exogenous surfactant replacement, caffeine citrate therapy, optimized nutritional fortifiers, and the highly judicious administration of postnatal systemic or inhaled corticosteroids to mitigate rampant inflammation and facilitate successful weaning from respiratory support.

Key Highlights

• In Germany, incident BPD cases are projected to increase from 2,851 to 3,057, reflecting a gradual rise linked to improved survival of preterm infants.
• Gender distribution shows a higher burden in males, with 55% male vs 45% female (2025).
• BPD remains a leading cause of long-term respiratory and neurodevelopmental complications in preterm infants.
• Lack of curative therapies underscores reliance on preventive and supportive care strategies.
• Increasing survival of extremely preterm infants is expected to expand the at-risk population, sustaining disease burden.

Market Overview

• The Germany BPD market is projected to grow from $15M to $72M, indicating strong expansion from a low base.
• Market growth is driven by:
• Increased survival rates of extremely preterm infants
• Adoption of advanced neonatal care and supportive therapies
• Despite a relatively small patient population, market value is supported by intensive care requirements and prolonged treatment duration.
• Emerging research in regenerative therapies, stem cell approaches, and anti-inflammatory agents is expected to shape future market potential.
• Future growth will depend on development of disease-modifying interventions targeting lung development and inflammation.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Airway Therapeutics, Inc.
• Medipost Co Ltd.
• OHB Neonatology Ltd

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)